Novo Nordisk's stock rose 6.32% after Q3 results showed the Wegovy oral pill took about 80% of new obesity drug prescriptions in the US, surpassing expectations despite price cuts and competition. The pill's rapid adoption is driving volume growth, offsetting a 30% price drop, and boosting the company's sales outlook and cash flow forecast. Wegovy's strong US launch and expanding international presence are key growth drivers, though challenges remain from competition and pricing pressure. Investors will watch if Wegovy maintains its market share and volume growth to sustain revenue.
As of Nov 05, 2026 01:01 WIB, Novo Nordisk's stock on Pluang is priced at USD 42.96, showing a 6.89% increase in one day, slightly above the article's reported 6.32% rise. The stock's market capitalization stands at $178.43 billion, with a notable dividend yield of 4.47%. This strong price movement aligns with the positive momentum from Wegovy's market performance.
Novo Nordisk reported strong Q3 results with revenue growth driven by its obesity care, especially the Wegovy pill, offsetting declines in diabetes products. International markets outperformed the U.S., and the company achieved a 40.1% adjusted opera...
Novo Resources announced a ~2,700 meter reverse circulation drilling program at its Tibooburra Gold Project in New South Wales, starting early November 2026. This follows recent surface sampling and mapping, with assays pending. The company is also r...
